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Abstract: Cutaneous manifestations of lupus erythematosus (CLE) are manifold,   presenting 
with unspecific skin manifestations or well-defined clinical dermatological entities. Their 
  relation to each other as well as to systemic lupus erythematosus is variable, yet diagnostically 
and   therapeutically challenging. Therapeutic decisions have to be based on the activity and 
distribution as well as the type of skin lesions and the extent of systemic disease. Limited skin 
manifestations may be amply tackled by topical therapy, so far, mainly relying on   corticosteroids. 
In many cases, however, internal treatment has to be combined by using antimalarials, in 
  addition to strict UV-protection. The advent of topical calcineurin inhibitors has contributed 
substantially to the armamentarium of external treatment options. By specifically interfering with 
intracytoplasmic signal transduction to activate the nuclear factor of activated T-cells (NF-AT), 
they are able to modulate various inflammatory mechanisms. The two available compounds, 
pimecrolimus and tacrolimus, do not induce the skin atrophy characteristic of corticosteroids. 
They have been studied in a number of case reports, but only in a few randomized,   comparative 
studies. Both are well-tolerated, but differentially effective in the various subsets of CLE. Further 
studies are needed to directly compare the two compounds to each other, as well as to topical 
corticosteroids, before final recommendations can be made.
Keywords: cutaneous lupus erythematosus, calcineurin inhibitors, topical therapy, systemic 
therapy
Introduction
Cutaneous manifestations within lupus erythematosus (LE) are manifold and their 
relation to systemic disease and its course and prognosis is often debated. Systemic 
lupus erythematosus (SLE) may present with skin symptoms either as the first   clinical 
manifestation or during the further course of the disease in up to 70% of cases.   However, 
dermatology has defined distinct clinical subsets of cutaneous LE (CLE), which may 
solely affect the skin or may eventually develop into systemic disease.1–4 In contrast to 
SLE as a chronic inflammatory multiorgan disease with variable clinical   appearance and 
course, the cutaneous subsets only show mild internal involvement (eg, mild   arthralgia 
and malaise).5 However, at first diagnosis and during the further course of the disease, 
systemic manifestation and organ involvement have to be carefully excluded to allow 
appropriate treatment.6 In addition, cutaneous side effects of any drug   treatment have 
to be carefully separated from disease-related manifestations.
The current classification of cutaneous lesions is still based on the initial   observation 
by Gilliam in 1977,7 who defined non-specific and specific skin   manifestations.8 
  Non-specific lesions comprise vascular lesions such as the syndrome of Raynaud, Biologics: Targets & Therapy 2011:5 submit your manuscript | www.dovepress.com
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  thrombophlebitis, and periungual teleangiectases.5,9 
  Furthermore, different clinical manifestations of cutane-
ous vasculitis are typical of such non-specific features 
such as   leukocytoclastic vasculitis, livedo racemosa, and 
  hypocomplementemic urticarial vasculitis. In addition, 
diffuse or mottled alopecia with telogen effluvium during 
disease flares-ups, erythema multiforme, or calcinosis cutis 
can be found. Whereas non-specific lesions are common 
in SLE, they may also be seen in association with specific 
cutaneous lesions.
Specific CLE lesions can be allocated and classified 
to distinct subtypes3 that may be variably interpreted by 
dermatologists and rheumatologists. Lesions are specified 
according to clinical, immunoserological, and histologi-
cal parameters, into acute cutaneous lupus erythematosus 
(ACLE), subacute cutaneous lupus erythematosus (SCLE), 
chronic cutaneous lupus erythematosus (CCLE) and intermit-
tent cutaneous lupus erythematosus (ICLE).
ACLE may present as the classical,   centrofacially-located 
butterfly rash in its localized form or as a generalized 
  maculopapular exanthema.5 Typically, patients are severely 
ill due to the underlying SLE and demonstrate diverse organ 
manifestations as well as anti-dsDNA antibodies.
In contrast to ACLE as a cutaneous manifestation of SLE, 
SCLE is sometimes interpreted as the borderline between 
strictly-limited dermal and systemic disease. Two clinically 
different forms are seen and present as a polycyclic anular 
eczema-like variant, and an erythemato-papulosquamous 
(psoriasiform) variant. Due to distinct ultraviolet light (UV) 
sensitivity, lesions are mainly found on sun-exposed areas 
like the forearms, the upper body, and neck, in a symmetrical 
distribution. Although the characteristic presence of anti-Ro/
SSA and anti-La/SSB autoantibodies indicates systemic 
disease, clinically, only mild arthralgia or myalgia are found 
in some cases. On the other hand, patients may fulfil up to 4 
criteria defined by the American College of Rheumatology 
for SLE.
Apart from UV light, various drugs have been described 
as inducers of SCLE, including terbinafine and angiotensin-
converting enzyme inhibitors.10,11
CCLE can be classified as discoid LE (DLE), LE 
  profundus (LEP) and chilblain LE (CHLE). In contrast to 
the other forms discussed so far, CCLE may result in distinct 
skin atrophia and scarring, which dictate early diagnosis and 
treatment to prevent permanent, disfiguring disease.
DLE is the most common form of CCLE, and of 
CLE as a whole group. It presents with well-demarcated 
  erythematosquamous plaques and characteristic pain when 
touched (the so-called “carpet tack sign”). Most lesions 
are located on the face and the scalp (localized form), but 
can also involve the lips or the oral mucosa, where sharply 
demarcated plaques and ulcers with irregular borders might 
mimic oral lichen planus.
As DLE may occur in 20% of patients with SLE, 
  systemic disease has to be excluded, even more so in cases 
of   disseminated manifestation (20%) of DLE, and in those 
5% of patients who show distinctly positive antinuclear 
antibodies (ANA).
LEP afflicts 1%–3% of all CLE patients.12,13 The 
  characteristic tender subcutaneous nodular infiltrations 
are located in the deep dermis and subcutaneous fat of the 
proximal extremities, the buttock and the head as well as 
trunk. They are referred to as LE panniculitis, and in cases 
with overlying discoid lesions, as LE profundus. However, 
both terms are often used interchangeably. Characteristically, 
lesions resolve with deep lipathrophia and scarring. Older 
lesions may even calcificate. Although up to 75% of patients 
show positive ANA titers (but no specific autoantibodies), the 
clinical manifestation of additional SLE is rare.1
CHLE is predominantly located at the nose and ears as 
well as at the distal extremities, especially the fingers and 
toes, with livid, red-to-purple nodules and plaques.5,14,15 
As CHLE presents in response to cold temperatures and 
humidity, it is often clinically and histologically difficult 
to differentiate from perniones. Although elevated ANA, 
anti-Ro, or positive rheumatoid factors are rarely found,14 
SLE may occur in about 20% of patients.
ICLE, or lupus erythematosus tumidus (LET), has only 
recently been allocated to CLE in a modified classification 
introducing an intermittent cutaneous LE.3,16 In contrast to the 
other CLE variants discussed so far, this very rare variant of 
LE lacks significant epidermal manifestations and scarring 
or atrophy.16 As the disease is eminently UV-sensitive, the 
characteristic erythematous urticarial papules and plaques 
are found in an anular or centrifugal presentation on the 
face, the upper proximal extremities, and the chest or trunk. 
The course and prognosis of ICLE are very good, and an 
  association with SLE uncommon. although elevated ANA 
levels are detectable in about 10%–30%, and anti-Ro or 
anti-La autoantibodies in about 5% of patients.
Pathogenesis
The pathogenesis of CLE, especially differential traits for 
the various subsets described above, is still unknown in 
detail, as is the varying relation to SLE.17 Various genetic 
and immunogenetic factors were shown to contribute Biologics: Targets & Therapy 2011:5 submit your manuscript | www.dovepress.com
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to CLE, but without giving distinct clues to differential 
effects.17 In addition, various environmental factors were 
identified, such as drugs,10 infections, and UV light, as 
contributing to the clinical manifestation of CLE, among 
other factors, and to explain its seasonal accumulation.18,19 
Within this context, the effects of UV light have been 
studied most extensively. An increased number of apop-
totic cells has been found either in skin biopsies from 
diseased skin or after experimental UV irradiation.20–22 
This accumulation may either result from an increased 
induction or delayed clearing of apoptotic cells. During 
these processes, autoimmune phenomena may be induced 
by increased accessibility of DNA, or Ro/La antigens, due 
to their expression on the cell membranes of apoptotic 
cells. In addition, a pro-inflammatory environment was 
shown in CLE lesions, with an increased expression of 
different cytokines such as interferons and TNF-(tumor 
necrosis factor) alpha, as well as a shift in T-cell immu-
nity. Most recently, CD4+, CD25+, and regulatory T-cells 
(Treg) were extensively studied. LE patients were shown to 
inappropriately suppress other T-cell populations and their 
proliferation in cutaneous lesions.17
These pathogenic traits result in characteristic histomor-
phologic changes. All CLE manifestation, apart from LET, 
will show a more or less distinct interface dermatitis and basal 
cell necrosis with thickening of the basement   membrane and 
a mononuclear periadnexial infiltrate. Whereas these features 
may be discrete in SCLE, hyperkeratosis and   epidermal 
  atrophy are prominent in DLE. Lobular panniculitis with 
dense infiltrates of lymphocytes and plasma cells, and 
  deposition of mucin between the adipocytes, are charac-
teristic of LEP. Increased dermal deposition of mucin and 
inflammation of the superficial periadnexal and perivascular 
areas are characteristic of LET.
Thus, anti-inflammatory and immunomodulatory 
  strategies seem most promising in the treatment of LE. 
Regarding the scarring propensity of CLE at most visible 
sites, an early and effective treatment is required.
Diagnostic procedures
As outlined above, the various subsets of CLE are variably 
related to SLE, either at the time of first diagnosis or during 
further disease progress. Therefore, careful examinations 
have to be performed to exclude any internal involvement, 
which apart from the joints, may affect important organs like 
the lungs, heart, kidneys, and the central nervous system.6 
Any further diagnostic examinations must rely on a careful 
case history and clinical examination, which will dictate 
histopathologic and laboratory tests, as well as technical 
examinations.
Basic laboratory screening will include a complete blood 
cell count, liver and renal function tests, acute phase proteins, 
and urinanalysis, whereas specific laboratory examinations 
comprise inflammatory, autoimmune and infectious disease 
parameters.6
If clinical- or laboratory-identified dysfunctions of 
internal organs are found, additional specific technical 
investigations related to lung, heart, and brain involvement 
are necessary, on an individual basis.
The special impacts of dermatology on the   diagnostics 
of CLE are with histological and immunohistolog-
ical   examinations, as well as the diagnostic testing 
of UV-sensitivity.5,21 Although the so-called lupus band test 
has lost most of its clinical significance, due to the availability 
of more sensitive anti-dsDNA tests, it may still be reason-
ably performed together with a histological examination 
of diseased skin (see above).23 Altogether, a final diagnosis 
may often be possible only by adding and balancing clinical, 
immunoserological, and histological features.
UV-sensitivity and provocation tests are hardly   necessary 
for final diagnosis, but will help evaluate the individual 
impact of photosensitivity, and thus increase the patient’s 
awareness of a correlation between UV exposure and skin 
lesion.6,21 Thus, compliance to adequate UV protection and 
treatment recommendations will be increased.
Treatment
Regarding therapeutic studies available on CLE, three major 
drawbacks must be considered. First, the different subsets 
of CLE have hardly been discriminated; too often, studies 
only refer to CLE as a group or, even worse, only to “skin 
  symptoms”. Secondly, if CLE subsets are differentiated, 
  different criteria for diagnosis of CLE subsets have been used 
that furthermore, have changed over time. Thirdly, activity 
criteria that have been defined and amply evaluated hereto 
are hardly available, resulting in yet another severe obstacle 
to direct comparison between different clinical studies.24 In 
2005, a new disease index score, the cutaneous lupus ery-
thematosus disease area and severity index (CLASI), was 
described for the evaluation of cutaneous lesions.25 In this 
score, “activity” is separated from “damage”. The CLASI 
score for activity decreases after successful therapy, whereas 
the damage score may increase in scarring forms of CLE. 
Therefore, this score correlates with the improvement of 
global skin health, pain, and itch, and is a useful tool to mea-
sure clinical responses to different treatments.26 Alternatively, Biologics: Targets & Therapy 2011:5 submit your manuscript | www.dovepress.com
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activity scores, such as the systemic lupus activity measure 
(SLAM), or the systemic lupus erythematosus disease activ-
ity index (SLEDAI) are available.24 However, they evaluate 
laboratory parameters and organ involvements that are not 
very representative of CLE. Recently, a standardized set of 
clinical core data has been suggested by the European Society 
for Cutaneous LE.27
Early diagnosis and treatment are mandatory for CLE, 
especially in cases with scarring disease, to prevent any 
residual and irreversible disfiguration. Furthermore, the risk 
of neoplastic transformation in long-standing hypertrophic 
and scarring disease has to be minimized. The choice of 
treatment will further rely on the disease subset of CLE, the 
extent of skin disease, as well as the presence and extent 
of internal organ involvement.6,28–30 Disease manifestations 
that are restricted to the skin only, and in a limited distribu-
tion, may amply be tackled with topical treatment, whereas 
  refractory or rapidly-progressing disease needs systemic 
therapy. Systemic corticosteroids are of limited effect in 
CLE and may be used in the initial phase of treatment, while 
highly inflammatory lesions are present, in doses well above 
0.5 mg/kg body weight. Regarding the systemic side-effects 
of corticosteroids, immunosuppressive or immunomodula-
tory drugs need to be added for their adjuvant effect.31 The 
mainstays of systemic treatment for more severe cases of 
CLE are antimalarials, mainly hydroxychloroquine and chlo-
roquine.32–34 Alternatives are dapsone, for more inflammatory 
lesions,35 and retinoids for distinctly hyperkeratotic lesions, 
as well as methotrexate.36 The antimetabolites   azathioprine, 
mycophenolate mofetil,37–39 and leflunomide show delayed 
and only inferior responses.6
Topical treatment options
Protection against UV light is recommended for all types 
of CLE. This can be achieved by textiles (eg, sun hat, 
  long-sleeved clothes), as well as additional physical and 
chemical sunscreens with sun protection filters for UVA 
and UVB well above factor 25. Patients with CLE should 
not work in professions or pursue leisure activities related to 
high UV exposure, and should not travel to Mediterranean 
and tropical countries without ample sun protection.
Especially in patients with scarring CLE or acute inflam-
matory lesions, additional make-up or camouflage may be 
psychologically helpful.40
The manifestations of all subsets of CLE can be improved 
by the topical application of corticosteroids, but to a   varying 
extent.6,28 Initial treatment should be performed once-daily 
with medium-strength topical corticosteroids such as 
  prednicarbate or methylprednisolone-aceponate (eg, for the 
face). At sites apart from the face, more potent   corticosteroids 
such as mometasonfuroat or betamethasone can be tried. An 
intralesional or occlusive application of potent   corticosteroids 
might be indicated in distinctly   hyperkeratotic lesions. 
  Alternatively, in these cases the topical application of 
  retinoids might be useful.
Any surgical or invasive procedures, such as tun-
able dye laser, dermabrasion, or excision should only be 
performed in individual cases of stable or, preferably, 
extinct disease lesions because of the possible Koebner 
phenomenon.19
Calcineurin inhibitors
With regard to the prominent unwanted effects of corticos-
teroids, especially with their long-term or repetitive use, 
alternative topical treatments are much needed. These have 
evolved with the advent of compounds that belong to the 
group of macrolactames, and are called calcineurin inhibi-
tors by their mode of action, which seems to rely primar-
ily on the decrease or blocking of cytokine production by 
activated T-lymphocytes.41–43 The therapeutic exploitation of 
calcineurin inhibition is well-established with ciclosporin, 
a cyclic peptide derived from a Scandinavian mold.42 It 
is licensed as a systemic agent to prevent the rejection of 
transplanted solid organs, as well as for the treatment of 
severe atopic eczema and psoriasis. Its clinical efficacy 
as a topical agent for skin diseases is, however, limited. 
Recently, 2 novel calcineurin inhibitors, tacrolimus and 
pimecrolimus, became available for topical application.44–47 
They are currently licensed and well-established for the 
treatment of moderate to severe atopic dermatitis, due to 
their prominent immunomodulatory effects.46,48–50 Over 
the past years, a variety of clinically and pathogenically 
different inflammatory skin diseases have been reported to 
respond to topical calcineurin inhibitors, among them, vari-
ous subsets of CLE. These reports cover single or few cases 
to date. However, placebo-controlled, double blind studies, 
and comparative, head-to-head studies of both substances 
are hardly available.
Calcineurin inhibitors: mode of action
Both of the available topical calcineurin inhibitors are purified 
from bacteria and further processed. Tacrolimus, or FK 506, 
was first described, as early as 1984, as a   product of soil   bacteria 
found at Mount Tsukuba in Japan. It shows close similarity Biologics: Targets & Therapy 2011:5 submit your manuscript | www.dovepress.com
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to other macrolide antibiotics.45–48 Thus, its name was coined 
from “Tsukuba macrolide   immunosuppression”. In contrast, 
pimcrolimus was   produced from   Streptomyces hygroscopicus 
as a semi-synthetic   derivate of ascomycin.44,51
The main targets of both compounds are T-lymphocytes, 
apart from eosinophilic and basophilic granulocytes, as well 
as mast cells, with an inhibition of their cytokine synthesis 
and release. Whereas the number of Langerhans cells in 
the epidermis remains unchanged, some of their functional 
parameters are modulated.52–54 In contrast, keratinocytes, 
fibroblasts, and endothelial cells are spared. This is in clear 
contrast to the pleiotropic effects of corticosteroids, which 
non-selectively modulate both the number and function of 
various cell subsets.
The immunomodulatory effects of tacrolimus and 
  pimecrolimus were investigated in vitro and found to result 
from binding to the intracytoplasmic protein makrophilin-12, 
which in turn inhibits calcineurin. This serine-threonine phos-
phatase plays an important role in activating the nuclear tran-
scription factor NFkB, which binds to the promotor regions 
of various cytokines, such as intereukin (IL)-2, TNF-α, 
interferon-γ, IL-4 and IL-10. The (indirect)   inhibition of 
NFκB by calcineurin inhibitors will thus result in a decrease 
of these cytokines.
Whereas the functional activities of both substances are 
similar, their different chemical structures result in   different 
lipophilia and penetration into the skin.   Pimecrolimus, 
being more lipophilic, shows a higher epidermal affinity, 
but lower penetration into the skin, and lower   resorption. 
In vivo   inflammatory models demonstrated a high 
  anti-inflammatory, but comparatively very low immunosup-
pressive activity. As no skin atrophy is observed, calcineurin 
inhibitors may be used at sensitive skin areas including the 
face, neck, and intertriginous areas.55,56 Interestingly, no 
increase of   bacterial or viral infection was found in clinical 
studies, which   underlines the beneficial characteristics of 
the compounds. Both are licensed for children above the 
age of 2 years for the treatment of moderate to severe atopic 
eczema. The only major side-effects are burning, erythema, 
and irritation, which are mostly reversible and transient. No 
significant systemic resorption,57 accumulation, or   systemic 
side effects are found, nor allergic,   photosensitizing, or pho-
totoxic properties. Though the photocarcinogenic activity, 
based on earlier studies, was minimal, the US Federal Drug 
Agency in 2005 imposed a black box warning on the long-
term use of both compounds, in   recognition of the limited 
clinical data and the possible risk of skin malignancies.50,58
Calcineurin inhibitors for CLe
Tacrolimus is available as 0.03% and 0.1% ointments and 
pimecrolimus as 1% cream. Small studies, mostly open-label, 
and case reports have been published for all 3 preparations, but 
mainly for 0.1% tacrolimus in the treatment of DLE. Only 3 
studies compared effects to a topical corticosteroid, and none 
to placebo. Two double-blind, placebo-controlled studies on 
pimecrolimus are available, one of these only as an abstract.
Recently, a number of reviews have summarized the use 
of calcineurin inhibitors in dermatology, covering the licensed 
use for atopic dermatitis as well as off-licence   applications 
in psoriasis, lichen planus, pyoderma   gangrenosum, and 
cutaneous lupus erythematosus.41,43,59
Walker et al60 treated two female patients with recalcitrant 
DLE with a combination of 0.05% clobetasole propionate and 
0.3% tacrolimus twice daily. After 6 and 8 weeks   respectively, 
almost complete resolution of the facial   manifestation could 
be observed. No side-effects were reported.
In a case series, Yoshimasu et al61 evaluated 11 patients 
(3 SLE, 4 DLE, 4 dermatomyositis) who applied 0.1% tacroli-
mus once daily. 6 patients (3 SLE, 1 DLE, 2 dermatomyositis) 
showed a marked regression of their skin lesions. However, 
4 patients (3 DLE, 1 dermatomyositis) were resistant to the 
therapy. In contrast to the lack of improvement in DLE, a 
good response was observed for facial erythematous lesions 
with edematous or telangiectatic changes in systemic LE 
and dermatomyositis. No adverse effects were induced by 
tacrolimus.
Böhm et al62 published a study of three patients with 
facial lesions of LE, one with systemic LE and a malar rash, 
one with annular subacute cutaneous LE, and another with a 
papular variant of subacute cutaneous LE. After adjunct treat-
ment with either 0.03% or 0.1% tacrolimus ointment for 5 to 
8 weeks, all patients experienced significant improvement. 
All patients received various systemic drugs at the same time, 
including antimalarials and systemic corticosteroids. In all 
patients, tacrolimus ointment was well-tolerated, except for 
transient pruritus and burning in one patient. No measurable 
peripheral blood levels of tacrolimus could be found in a 
representative laboratory test in one patient.
Bacman et al63 treated 1 patient with LET using tacroli-
mus 0.1% ointment on one side of the face, compared to 
  methylprednisolone on the other side, with good   clinical 
response and tolerability after 4 weeks, and complete clearing 
upon prolonged application. No reference is made, however, 
to the course of the skin disease after stopping the topical 
treatment.Biologics: Targets & Therapy 2011:5 submit your manuscript | www.dovepress.com
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Kanekura et al64 treated 3 SLE patients with malar rash using 
topical 0.1% tacrolimus ointment twice-daily for 3 weeks on one 
half of the face, and compared the response to the untreated side. 
After 3 weeks, erythema on the treated side improved in all 3 
patients. No burning sensation, skin-tingling, irritation, or pru-
ritus at the site of application of the ointment was reported.
De la Rosa Carrillo and Christensen65 reported a female 
patient with long-standing DLE of her face and scalp who was 
treated with tacrolimus 0.1% ointment. Interestingly, apart from 
clearing of facial lesions, regrowth of terminal hair on most of 
the scalp was observed. No side-effects were reported.
Drüke et al66 studied a 51-year-old female patient with 
SLCE who was treated with 0.1% tacrolimus twice-daily. 
Almost complete resolution was found after an 8-week 
treatment, which persisted to a 3-month follow-up. The only 
complaint of the patient was a slight burning pain at the 
beginning of the treatment.
Lampropoulos et al67 studied 12 patients with   recalcitrant 
CLE, 6 of them with DLE, 4 with SCLE, and 2 with 
SLE using 0.1% tacrolimus ointment for a minimum of 
6 weeks. The clinical response was evaluated by patients’ 
and   physicians’ assessments and documented with clinical 
  photographs at baseline and at the end of the treatment. One 
patient stopped the treatment due to unwanted local effects 
such as burning and peeling. Six of the other 11 patients 
improved distinctly. One patient showed minor improvement 
of his facial lesions, while 4 patients remained unchanged. 
Within the 3 clinical subsets included, only 2 of the 4 
patients with SCLE showed significant regression of their 
lesions, while the other 2 remained unchanged. Two of the 
6 DLE patients showed “certain” improvement (1 with only 
minor improvement, and 3 with no response at all). On the 
other hand, significant improvement of their skin rashes was 
found in the 2 SLE patients.
Table 1 List of clinical studies on topical calcineurin inhibitors for CLe
Drug compound CLE subtype Protocol Study type Reference
Tacrolimus 0.3% 
combined with 
clobethasol 0.05%
DLe 6–8 weeks twice daily case report walker et al60
Tacrolimus 0.1% SLe, DLe 4 weeks once daily case report Yoshimasu et al61
Tacrolimus 0.1% or 
0.03%
SLe, SCLe 5–8 weeks once or  
twice daily
case report Böhm et al62
Tacrolimus 0.1% LeT 4 weeks twice daily case report Bacman et al63
Tacrolimus 0.1% SLe 4 weeks twice daily case report Kanekura et al64
Tacrolimus 0.1% DLe 8 weeks twice daily case report de la Rosa Carillo and 
Christensen65
Tacrolimus 0.1% SCLe 8 weeks twice daily case report Drüke et al66
Tacrolimus 0.1% SLe, SCLe, DLe .6 weeks twice daily open label study Lampropoulos et al67
Tacrolimus 0.1% SCLe 3 weeks twice daily case report Meller et al68
Tacrolimus 0.1% DLe 12 weeks twice daily open label study Heffernan et al69
Tacrolimus 0.1% DLe 4–8 weeks twice daily case report Sugano et al70
Tacrolimus 0.1% SLe, DLe 3 weeks twice daily 
4-week follow-up
case report von Pelchrzim et al71
Tacrolimus 0.1% vs 0.05% 
clobetasol proprionate
SLe, SCLe, DLe 4 weeks twice daily randomized double blind 
bilateral comparison
Tzung et al72
Tacrolimus 0.03% SCLe 6 weeks case report Cooper et al73
Tacrolimus 0.3%/0.005  
clobetasol vs.tacrolimus 0.1%
DLe, SCLe, SLe twice daily retrospective study  Madan et al.74
Tacrolimus 0.03% linear DLe one year case report Kawachi et al.75
Tacrolimus 0.1% DLe 8 weeks twice daily case report Han et al.76
Pimecrolimus 1% cream DLe 8 weeks twice daily case report Han et al.76
Pimecrolimus 1% cream not given case report Zabawski77
Pimecrolimus 1% cream SLe, SCLe  
DLe, LeT
3 weeks twice daily 
8-week follow-up
open label study Kreuter et al78
Pimecrolimus 1% cream DLe 8 weeks twice daily open label study Tlacuilo-Parra et al79
Pimecrolimus 1% cream 
vs placebo
SCLe, DLe 4 weeks twice daily 
4-week follow-up
randomized double blind, 
placebo controlled, bilateral 
comparison 
Sticherling et al80 
Pimecrolimus 1% cream 
vs 0.1% betamethasone
DLe 8 weeks twice daily randomized double blind Barikbin et al81 Biologics: Targets & Therapy 2011:5 submit your manuscript | www.dovepress.com
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Meller et al68 studied an 83-year-old female patient with 
SCLE on the upper extremities and upper trunk, which 
improved after a 3-week treatment twice-daily with 0.1% 
tacrolimus ointment. The authors judged the compound to 
be an effective and safe alternative to the established topical 
treatment of CLE. No side-effects were reported.
Heffernan et al69 conducted an open-label pilot study 
including 5 patients with DLE who were treated with 0.1% tac-
rolimus ointment twice daily for 12 weeks. Two target lesions 
were monitored every 4 weeks, assessing their size (diameter), 
erythema, scarring, and thickness on a 5-point scale. Only 3 
patients completed the study, with mild,   moderate, and marked 
improvements, respectively, and apparently no side-effects. 
This study included only a low number of patients, without a 
control group, using a non-validated skin score.
Sugano et al70 studied 4 Japanese patients with DLE who 
were successfully treated with topical tacrolimus ointment 
(0.1%) twice daily. The erythematous plaques diminished 
distinctly after 4–8 weeks. No local adverse effects were 
observed.
Von Pelchrzim et al71 observed variable responses of facial 
lesions but absence of adverse events in 4 patients suffering 
from SLE and DLE when treated with topical tacrolimus 
0.1% ointment for up to 2 months. Two patients (1 with 
SLE and 1 with DLE) showed marked regression of their 
skin lesions after 3 weeks of treatment, whereas the others 
showed no response.
Tzung et al72 conducted a randomized, double-blind 
study comparing the efficacy and safety of 0.1% tacroli-
mus ointment and 0.05% clobetasol propionate ointment 
in the treatment of facial CLE. 20 patients (13 with malar 
rash of SLE, 4 with DLE, and 1 with SCLE) applied 0.1% 
tacrolimus ointment to the affected areas on one side of 
the face and 0.05% clobetasol propionate ointment to the 
other side of the face. Skin lesions were assessed at each 
visit (weeks 0, 1, 2, 3, 4, and post-treatment week 4) using 
a 7-point rating scale that included erythema, desquama-
tion, and induration. To improve the penetration of the 
compound into the skin, a standardized microdermabrasion 
was performed after each assessment, once-weekly. Of 
the enrolled 20 patients, 11 women and 7 men completed 
the study. There was no significant difference between 
tacrolimus and clobetasol. All lesions worsened at week 8 
(ie, 4 weeks after stopping the treatment), although they 
were still better than at baseline. However, 11 patients 
(61%) developed telangiectasia on the clobetasol side of 
the face as early as week 3. This study clearly shows similar 
effects of tacrolimus and clobetasol, yet distinct differences 
in side-effects. The clinical effects are restricted to the 
time of treatment, with slow deterioration after stopping 
the therapy.
Cooper et al73 studied for 2 months a 6-month-old girl 
with SCLE born to a mother with Sjögren syndrome. Her 
facial lesions resolved completely with application of 0.03% 
tacrolimus ointment for 6 weeks.
Madan et al.74 recently published a retrospective study on 
the topical treatment with tacrolimus 0.3% in fixed combina-
tion with clobetasolepropionat 0.05% twice daily in therapy 
resistant CLE. Eleven of 13 patients with CLE (DLE n=11, 
SCLE n=1, SLE n=1) showed a good to excellent response 
compared to 5 patients who were treated with 0,1% tacroli-
mus without corticosteroid. The rationale of this study is 
not evident as the higher efficacy of tacrolimus (0.3%) plus 
clobetasole compared to monotherapy with tacrolimus (0.1%) 
is all but surprising. The concentration of 0.3% has neither 
been evaluated nor licensed. In addition, the study comprises 
a low number of patients. 
Two most recent publications reported on the successful 
administration of calcineurin inhibitors in DLE. Kawachi 
et al.75 treated the rare case of a six year old Japanese girl 
with linear DLE following the lines of Blaschko. Clinical 
improvement was seen after prolonged treatement with topi-
cal tacrolimus 0.03% over one year. Similarly, Han et al.76 
treated four patients with DLE successfully and with good 
tolerability using either tacrolimus 0.1% or pimecrolimus 
twice daily for 8 weeks. 
The number of case reports and studies on pimecroli-
mus is much lower than for tacrolimus. Some are discussed 
below.
Zabawski77 was the first to describe a single patient with 
facial plaques of discoid lupus erythematosus, who was 
treated with pimecrolimus 1% cream, resulting in moderate 
improvement. However, the treatment protocol, the duration 
of treatment, adverse events, and method of assessing the 
improvement are not mentioned.
Kreuter et al78 presented data from 11 patients with 
  different forms of cutaneous lupus erythematosus (4 DLE, 
2 SCLE, 3 SLE, 2 LET) who were treated in an open, 
  uncontrolled study with pimecrolimus 1% cream under 
semiocclusive conditions twice-daily for 3 weeks. Skin 
involvement was assessed before and after therapy by means 
of a clinical score. A significant regression of skin lesions 
by 52% was observed after therapy in all patients, and the 
improvement of skin status was sustained in most of the 
patients during a follow-up period of 8 weeks. In contrast 
to long-standing and distinctly hyperkeratotic DLE, early Biologics: Targets & Therapy 2011:5 submit your manuscript | www.dovepress.com
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erythematous lesions of SCLE and LE tumidus showed a 
better response. Minimal transient burning was observed in 
only one case, at the beginning of treatment.
Tlacuilo-Parra et al79 conducted an open-label, phase II trial 
on 10 patients with discoid lupus who were treated with pime-
crolimus 1% cream twice-daily for 8 weeks. They assessed 
skin involvement with a clinical severity score,   quality of 
life, patient improvement, and toxicity.   Furthermore, clini-
cal changes were documented by skin biopsy at baseline and 
at the end of treatment. In all patients, a 56% improvement 
in the clinical severity score for skin   damage was observed 
after therapy, as well as a 46% improvement in the quality of 
life score. 50% of the patients qualified their skin improve-
ment as marked, 40% as moderate and 10% as slight. The 
treatment was well-tolerated, apart from short-term minimal 
erythema and pruritus.
Sticherling et al80 conducted a double-blind, placebo-
controlled study of 25 patients with CLE (13 DLE, 12 SCLE), 
using a twice-daily application of 1% pimecrolimus cream or 
placebo for 4 weeks. The local tolerance was very good, and 
similar in both groups. In both groups, the skin score compris-
ing erythema, infiltration, scaling, and diameter of lesions 
decreased from 5.5 before treatment to 2.8 after treatment. 
No differences of efficacy were found upon stratification of 
DLE and SCLE. The amount of cream used in either group 
was identical, excluding a possible bias. During the 4-week, 
blinded follow-up period, the skin score increased to 3.4 in 
both groups.
Most recently, Barikbin et al81 conducted a randomized, 
double-blind pilot study of ten patients with facial lesions 
of DLE, comparing topical pimecrolimus 1% cream and 
  topical betamethasone 17-valerate 0.1% cream twice daily 
for 8 weeks. Using a combined score based on the evaluation 
of erythema, infiltration, and presence of scales, a distinct, 
however not statistically significant, improvement was found 
in both groups, with a decrease of 86% and 73% respectively 
for pimecrolimus and betamethasone. This study contained 
a low number of patients and is in clear contrast to other 
reports on rather poor responses of DLE. 
Altogether 144 patients have been studied, in 23 case 
reports or studies, who were treated with either   pimecrolimus 
(n = 59 in 6 publications) or tacrolimus (n = 85 in 17 publica-
tions). There are 15 case reports, with varying numbers of 
patients all but one using tacrolimus, and 4 studies in either 
open-label (2 each on pimecrolimus and tacrolimus) or ran-
domized, double-blind (n = 3) settings. The latter 3 compared 
2 agents, either in bilateral fashion or within separate treat-
ment arms. Two studies used both agents on either side of the 
face, one study comparing 0.1% tacrolimus ointment to 0.05% 
clobetasol propionate in combination with microdermabra-
sion once weekly,72 another comparing 1% pimecrolimus to 
placebo.80 The third study compared 1% pimecrolimus to 
betamethasone 17-valerate 0.1% cream in 2 separate treat-
ment groups.81 Regarding the different clinical subsets of 
CLE, 9 reports on 37 patients examined DLE only (4 using 
tacrolimus, 3 using pimecrolimus), and only 3 case reports 
covered SCLE. All other publications comprised at least 2 of 
the clinical CLE subsets. The respective clinical definitions 
and activity scoring have been grossly divergent, making a 
direct comparison of the studies very difficult. Furthermore, 
prior or concomittent treatment has been varying.
Conclusion
In summary, both of the available topical calcineurin inhibi-
tors are generally well tolerated, but effective to a varying 
extent in the diverse CLE subsets. Whereas cutaneous lesions 
of SLE generally respond well, only slight effects are dem-
onstrated for SCLE. For DLE, the results are less convincing 
because distinct hyperkeratosis will result in a low penetration 
of the compounds.
A number of general reviews have addressed the use 
of calcineurin inhibitors in dermatology beyond atopic 
dermatitis and positively judged their effects on cutaneous 
autoimmune diseases including CLE. At the same time, all 
authors demand further clinical studies.82-88
Due to the lack of comparative data, no clear-cut refer-
ence can be made to the differential effectiveness of either 
reagent. Monotherapy in highly active and disseminated cases 
does not seem promising, especially not in DLE, whereas 
SCLE and SLE skin lesions seem to respond better. In more 
severe and recalcitrant cases, combined systemic treatment 
with antimalarials is advised. Apart from these, more gen-
eral conclusions and recommendations, no evidence-based, 
evaluated protocols for the use of calcineurin inhibitors in 
CLE are available but may be deduced from their effective 
clinical use in atopic eczema.46,89 Here, the initial treatment 
of highly inflammatory lesions with topical corticosteroids 
is followed by topical calcineurin inhibitors. A chronic, 
long-term treatment is licenced for mildly inflammatory or 
prodromal lesions with an alternative treatment every other 
day or weekend-only treatment as an alternative.
The fear of a UV-related increase in skin tumors seems 
overrated for CLE, as the patients are advised to strictly 
adhere to UV protection.90
Consequently, with the advent of topical   calcineurin 
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became available. They are, at most, comparable to topical 
corticosteroids but with fewer unwanted effects. However, 
before final decisions and recommendations on their use 
for CLE are made, multicenter studies, with clearly defined 
classification and activity criteria, on a sufficient number 
of individuals are needed, which directly compare the two 
calcineurin inhitors to either placebo, topical   corticosteroids, 
and/or to each other.
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